Dodge & Cox Rotates From Defensives Into Scaled Tech and Fee Engines

Rising-conviction buys cluster around three themes: global software/platform scale, franchise insurers, and industrials levered to infrastructure and HVAC/energy efficiency.

• Microsoft (portfolio_pct 2.43%) was lifted by +60.7% in share count, a massive reinvestment of about $1.67B. That turns a long-held winner (up 98.3% vs their avg cost) into a core pillar, signaling comfort paying up for durable cloud and productivity economics rather than hunting only for optically cheap cyclicals.
• Booking saw a +36.3% add worth roughly $1.12B, a clear endorsement of global travel demand and the structural power of online distribution. They’re willing to own a high-ROIC consumer platform alongside more staid holdings.
• Arthur J Gallagher and Willis Towers Watson both saw meaningful adds (AJG up +735.2%, WTW up +5.9%), growing a specialty insurance/advisory basket that throws off recurring fees and underwriting cash flows. Combined with a +3.4% lift in Aon, this looks like a deliberate build-out of an insurance-broker compounder sleeve.
• Carrier nearly doubled (+98.4%) and Brookfield rose +43.4%, showing appetite for industrial and asset-management names whose earnings are tethered to capex cycles, infrastructure, and real assets, not just consumer demand.
• Smaller health care adds in Cigna, UnitedHealth, Humana, GE HealthCare and Zimmer Biomet show they’re rotating within the sector toward managed care and medtech rather than broad pharma exposure.

On the sell side, Dodge & Cox is clearly harvesting strength in mature winners and distancing themselves from lower-conviction defensives.

• FedEx is the biggest funding source, with shares cut -35.9% (about $1.99B trimmed). After a huge gain vs their $138.6 entry (up 174.2%), they’re cashing in on a cyclical transport win rather than pressing it into a slowing freight backdrop.
• Sanofi was slashed -47.8% (roughly $1.30B out), and GSK was cut -14.4% (about $543.9M). That’s a material retreat from European big pharma, especially with Sanofi at a loss relative to their cost. It looks more like a structural downgrade of the thesis than a simple risk trim.
• Norfolk Southern (-35.0%, nearly $966.1M trimmed) and CVS (-17.2%, about $770.6M) highlight a broader move away from classic U.S. defensives — rails and retail health — where regulatory, labor and execution risk are rising while upside looks capped.
• In industrials and energy, they took measured profits: Johnson Controls (-4.8%), RTX (-5.6%), Occidental (-6.8%) and Baker Hughes (-12.0%) are all long-held winners. These are not thesis reversals so much as cash sources to fund Microsoft, insurance brokers, Carrier and Brookfield.
• Consumer staples were also clipped via a -10.4% trim in Anheuser-Busch, leaning away from slow-growth, politically noisy brands toward higher-ROIC platforms and services.

At the sector level, the rotation is incremental but purposeful. Finance rose to 17.82% from 16.86%, technology to 11.98% from 10.81%, and real estate to 8.05% from 7.39%, while health care, consumer staples and energy all slipped.

The finance build isn’t just more banks; it’s a tilt to fee and insurance franchises. Adds in Arthur J Gallagher, Willis Towers Watson, Aon and a slightly higher MetLife position sit alongside trims in value banks like Bank of New York Mellon, Wells Fargo and Capital One. They’re trading pure rate/credit beta for insurance and advisory cash flows.

In tech, the story is almost entirely Microsoft plus maintaining, not expanding, mega-cap internet exposure: small trims in Alphabet and Meta offset the MSFT build, turning the tech sleeve into a more balanced mix of software, digital ads and electronics (via TE Connectivity). Real estate’s higher weight reflects larger stakes in Brookfield, Fiserv-labeled real-estate-related processing, SBA Communications and other REIT-like infrastructure plays.

Health care fell to 17.77% from 19.04% as capital came out of Sanofi, GSK, Gilead, Regeneron and Elanco and was partially redeployed into Cigna, UnitedHealth, Humana, GE HealthCare and Zimmer. Consumer staples dropped as CVS and Anheuser-Busch were trimmed, reinforcing the shift away from slow, regulated earnings streams.

Taken together, the quarter shows Dodge & Cox leaning into a barbell of global platforms and resilient cyclicals, funded by shrinking classic defensives. They’re not chasing speculative growth; they’re scaling into dominant franchises with visible cash flows and pricing power.

On one side sit Microsoft, Booking, Coupang and the cable/wireless trio (Comcast, Charter, T-Mobile), plus real-asset ecosystems like Brookfield and SBA Communications. On the other side, they retain heavy stakes in industrials (Johnson Controls, RTX, Carrier, Fortive) and energy (Occidental, Suncor), but with some profit-taking that suggests discipline about cyclicality and capital intensity.

The notable step-back is in traditional health care and pharma, where the opportunity cost versus platforms and fee engines appears too high. Cutting Sanofi and GSK while upgrading managed care and medtech points to a more selective, margin- and growth-focused health care stance.

If this rotation continues, expect further migration of capital into insurance brokers, asset managers and infrastructure-tied industrials, with tech anchored around a handful of scaled winners rather than a broad basket. The 13F doesn’t predict returns, but it does make one thing clear: Dodge & Cox is quietly rewriting its value playbook for a world where the most durable moats are in software, networks and fee franchises, not just smokestacks and pipelines.